 <h1>Peginterferon alfa-2a Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to peginterferon alfa-2a: subcutaneous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Alpha interferons may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Clinical and laboratory monitoring is recommended. If severe or worsening signs or symptoms of these conditions occur, treatment should be discontinued.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, peginterferon alfa-2a may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking peginterferon alfa-2a:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chills</li>
<li>cough</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>fever</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>sore throat</li>
<li>tiredness</li>
<li>trouble sleeping</li>
<li>trouble concentrating</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bone pain</li>
<li>chest pain or discomfort</li>
<li>confusion</li>
<li>constipation</li>
<li>depressed mood</li>
<li>dizziness</li>
<li>dry skin and hair</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>feeling cold</li>
<li>hair loss</li>
<li>headache</li>
<li>heart murmur</li>
<li>hives</li>
<li>hoarseness or husky voice</li>
<li>lightheadedness</li>
<li>muscle cramps and stiffness</li>
<li>pale skin</li>
<li>rapid, shallow breathing</li>
<li>slowed heartbeat</li>
<li>sneezing</li>
<li>stomach pain</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>weight gain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Accumulation of pus in the arms or legs</li>
<li>blistering, peeling, loosening of the skin</li>
<li>decreased urination</li>
<li>diarrhea</li>
<li>dry mouth</li>
<li>increase in heart rate</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>red, irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>seizures</li>
<li>sunken eyes</li>
<li>swollen, red, tender area of infection in the arms or legs</li>
<li>thirst</li>
<li>wrinkled skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of peginterferon alfa-2a may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>cracked, dry, scaly skin</li>
<li>crusting, irritation, itching, or reddening of the skin</li>
<li>fear</li>
<li>feeling unusually cold, shivering</li>
<li>hair loss or thinning of the hair</li>
<li>muscle or joint pain</li>
<li>nervousness</li>
<li>numbness</li>
<li>pain</li>
<li>rash</li>
<li>redness</li>
<li>scarring</li>
<li>soreness</li>
<li>stinging</li>
<li>swelling</li>
<li>tenderness</li>
<li>tingling</li>
<li>ulceration</li>
<li>vomiting</li>
<li>warmth</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Belching</li>
<li>blurred vision</li>
<li>heartburn</li>
<li>indigestion</li>
<li>memory problems</li>
<li>stomach discomfort or upset</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Change of hearing</li>
<li>loss of hearing</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to peginterferon alfa-2a: subcutaneous kit, subcutaneous solution</i></p><h3>General</h3><p>During hepatitis C studies, at least 1 serious side effect was reported in 10% of chronic hepatitis C (CHC) patients and 19% of CHC patients coinfected with HIV.  The most common serious side effect was bacterial infection (including sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia).  Other serious side effects were suicide, suicidal ideation, psychosis, aggression, anxiety, drug abuse and drug overdose, angina, hepatic dysfunction, fatty liver, cholangitis, arrhythmia, diabetes mellitus, autoimmune phenomena (e.g., hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis), peripheral neuropathy, aplastic anemia, peptic ulcer, gastrointestinal bleeding, pancreatitis, colitis, corneal ulcer, pulmonary embolism, coma, myositis, cerebral hemorrhage, thrombotic thrombocytopenic purpura, psychotic disorder, and hallucination.  The most common side effects were psychiatric reactions (including depression, insomnia, irritability, anxiety), influenza-like symptoms (such as fatigue, pyrexia, myalgia, headache, rigors), anorexia, nausea and vomiting, diarrhea, arthralgias, injection site reactions, alopecia, and pruritus.  Psychiatric disorders, influenza-like syndrome (e.g., lethargy, fatigue, headache), dermatologic disorders, gastrointestinal disorders, and laboratory abnormalities (thrombocytopenia, neutropenia, anemia) were the most common reasons for discontinuation of therapy.</p>
<p></p>
<p>In clinical trials, patients with chronic hepatitis B had similar side effects as CHC patients using peginterferon alfa-2a monotherapy, except for exacerbations of hepatitis.  The most common or important serious side effects in the hepatitis B studies were infections (sepsis, appendicitis, tuberculosis, influenza), hepatitis B flares, thrombotic thrombocytopenic purpura, pyrexia, headache, fatigue, myalgia, alopecia, and anorexia.  Therapy was discontinued most often due to laboratory abnormalities (neutropenia, thrombocytopenia, ALT elevation).<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Headache (monotherapy: up to 54%; combination therapy: 43%), dizziness excluding vertigo (monotherapy: 16%; combination therapy: 14%), and memory impairment (monotherapy: 5%; combination therapy: 5%) have been reported in CHC patients.</p>
<p></p>
<p>Tinnitus was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.</p>
<p></p>
<p>A 40-year-old male coinfected with hepatitis C virus and HIV experienced chorea and akathisia coincident with peginterferon alfa-2a therapy.  He was administered subcutaneous peginterferon alfa-2a 180 mcg weekly and oral ribavirin 1 g daily.  At week 20 of therapy, the patient presented to the clinic complaining of irritability, difficulty in sleeping, and prominent choreiform involuntary movements with myoclonic activity of the upper and lower extremities.  He was diagnosed with chorea and akathisia.  He was treated with ropinirole, propranolol, and clonazepam.  Peginterferon alfa-2a and ribavirin were discontinued with complete resolution of symptoms after 5 days.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Dizziness (up to 89%), headache (up to 56%), concentration impairment</p>
<p><b>Common</b> (1% to 10%): Vertigo, syncope, migraine, memory impairment, weakness, hypoesthesia, hyperesthesia, paresthesia, tremor, taste disturbance, somnolence, tinnitus</p>
<p><b>Uncommon</b> (0.1% to 1%): Peripheral neuropathy, hearing loss</p>
<p><b>Rare</b> (0.01% to 0.1%): Cerebral hemorrhage, coma, convulsions, facial palsy</p>
<p><b>Frequency not reported</b>: Cerebral ischemia, chorea and akathisia</p>
<p><b>Postmarketing reports</b>: Seizures, hearing impairment<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Influenza-like signs/symptoms, fatigue/asthenia (up to 65%), pyrexia (up to 54%), fatigue (up to 51%), rigors (up to 35%), asthenia (up to 30%), pain (up to 11%), overall resistance mechanism disorders (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Fever, chills, chest pain, influenza-like illness, malaise, lethargy, shivering, hot flushes, thirst, infections (fungal, viral, bacterial), peripheral edema, flushing, earache</p>
<p><b>Rare</b> (0.01% to 0.1%): Mucosal hyperpigmentation, otitis externa, substance overdose</p>
<p><b>Frequency not reported</b>: Bacterial infections (e.g., sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia), infections (appendicitis, tuberculosis, influenza)<sup>[Ref]</sup></p><p>Influenza-like signs and symptoms (fatigue/asthenia [monotherapy: 56%; combination therapy: 65%], pyrexia [monotherapy: up to 54%; combination therapy: 41%], rigors [monotherapy: 35%; combination therapy: 25%], pain [monotherapy: 11%; combination therapy: 10%]) and overall resistance mechanism disorders (monotherapy: 10%; combination therapy: 12%) have been reported in CHC patients.</p>
<p></p>
<p>The most common or important serious side effects reported during hepatitis B studies have included infections (sepsis, appendicitis, tuberculosis, influenza).</p>
<p></p>
<p>Fatigue has been reported in 24% of patients during hepatitis B studies.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Myalgia (monotherapy: up to 37%; combination therapy: 40%), arthralgia (monotherapy: 28%; combination therapy: 22%), and back pain (monotherapy: 9%; combination therapy: 5%) have been reported in CHC patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Myalgia (up to 44%), arthralgia (up to 32%)</p>
<p><b>Common</b> (1% to 10%): Back pain, arthritis, muscle weakness, bone pain, neck pain, musculoskeletal pain, muscle cramps</p>
<p><b>Rare</b> (0.01% to 0.1%): Myositis</p>
<p><b>Frequency not reported</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Neutropenia (monotherapy: 21%; combination therapy: up to 40%), lymphopenia (monotherapy: 3%; combination therapy: 14%), anemia (monotherapy: 2%; combination therapy: up to 14%), and thrombocytopenia (monotherapy: 5%; combination therapy: up to 8%) have been reported in CHC patients.</p>
<p></p>
<p>Moderate (absolute neutrophil count [ANC] 0.5 to 0.749 x 10[9]/L: 24%) and severe (ANC less than 0.5 x 10[9]/L: 5%) neutropenia was reported in patients using peginterferon alfa-2a plus ribavirin for 48 weeks.</p>
<p></p>
<p>In 1 study, CHC patients with advanced fibrosis or cirrhosis and baseline platelet counts as low as 50,000/mm3 were treated for 48 weeks.  Hematologic laboratory abnormalities in the first 20 weeks included ANC less than 750/mm3 (30%), hemoglobin less than 10 g/dL (26.3%), and platelets less than 50,000/mm3 (13%).</p>
<p></p>
<p>Neutropenia (40%), anemia (14%), and thrombocytopenia (8%) have been reported during treatment with peginterferon alfa-2a plus ribavirin in CHC patients coinfected with HIV.  Decrease in ANC levels below 500 cells/mm3 (monotherapy: 13%; combination therapy: 11%), decrease in platelets below 50,000/mm3 (monotherapy: 10%; combination therapy: 8%), and hemoglobin less than 10 g/dL (monotherapy: 7%; combination therapy: up to 28%) were reported in coinfected patients.</p>
<p></p>
<p>Laboratory abnormalities (thrombocytopenia, neutropenia, anemia) were among the most common reasons given for discontinuation of therapy.</p>
<p></p>
<p>The most common or important serious side effects reported during hepatitis B studies have included thrombotic thrombocytopenic purpura.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Neutropenia (up to 40%), anemia (up to 28%), lymphopenia (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Thrombocytopenia, lymphadenopathy</p>
<p><b>Rare</b> (0.01% to 0.1%): Pancytopenia</p>
<p><b>Very rare</b> (less than 0.01%): Aplastic anemia, idiopathic or thrombotic thrombocytopenic purpura</p>
<p><b>Frequency not reported</b>: Leukopenia, decreased hemoglobin, decreased absolute CD4+ cell count (without decrease in CD4+ cell percentage)</p>
<p><b>Postmarketing reports</b>: Pure red cell aplasia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 40%), diarrhea (up to 26%), nausea/vomiting (up to 25%), abdominal pain (up to 15%), vomiting (up to 13%), upper abdominal pain (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Dry mouth, dyspepsia, dysphagia, mouth ulceration, gingival bleeding, glossitis, stomatitis, flatulence, gastritis, gingivitis, cheilitis, constipation, oral candidiasis</p>
<p><b>Uncommon</b> (0.1% to 1%): Gastrointestinal bleeding</p>
<p><b>Rare</b> (0.01% to 0.1%): Tongue hyperpigmentation, peptic ulcer, pancreatitis</p>
<p><b>Frequency not reported</b>: Colitis, ischemic colitis, reversible pancreatic reaction (i.e., increased amylase/lipase with or without abdominal pain)</p>
<p><b>Postmarketing reports</b>: Tongue pigmentation<sup>[Ref]</sup></p><p>Gastrointestinal side effects were among the most common reasons given for discontinuation of therapy.</p>
<p></p>
<p>Nausea/vomiting (monotherapy: 24%; combination therapy: 25%), diarrhea (monotherapy: 16%; combination therapy: 11%), abdominal pain (monotherapy: 15%; combination therapy: 8%), dry mouth (monotherapy: 6%; combination therapy: 4%), and dyspepsia (monotherapy: less than 1%; combination therapy: 6%) have been reported in CHC patients.</p>
<p></p>
<p>Cheilitis was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects were among the most common reasons given for discontinuation of therapy.</p>
<p></p>
<p>Irritability/anxiety/nervousness (monotherapy: 19%; combination therapy: 33%), insomnia (monotherapy: 19%; combination therapy: 30%), depression (monotherapy: 18%; combination therapy: 20%), concentration impairment (monotherapy: 8%; combination therapy: 10%), and mood alteration (monotherapy: 3%; combination therapy: 5%) have been reported in CHC patients.</p>
<p></p>
<p>Affect lability and apathy were reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.</p>
<p></p>
<p>Impairment of desire, sexual satisfaction affected (potentially), and sexual dysfunction have been reported with peginterferon alfa-2a plus ribavirin in male patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Insomnia (up to 36%), irritability/anxiety/nervousness (up to 33%), irritability (up to 28%), depression (up to 27%), anxiety</p>
<p><b>Common</b> (1% to 10%): Concentration impairment, mood alteration, nightmares, aggression, emotional disorders, nervousness, decreased libido, affect lability, apathy</p>
<p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation, hallucinations</p>
<p><b>Rare</b> (0.01% to 0.1%): Suicide, psychotic disorder</p>
<p><b>Frequency not reported</b>: Psychosis, relapse of drug abuse/overdose, impairment of desire, sexual satisfaction affected (potentially), sexual dysfunction, mania, bipolar disorders</p>
<p><b>Postmarketing reports</b>: Homicidal ideation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic side effects were among the most common reasons given for discontinuation of therapy.</p>
<p></p>
<p>Alopecia (monotherapy: up to 23%; combination therapy: 28%), pruritus (monotherapy: 12%; combination therapy: 19%), dermatitis (monotherapy: 8%; combination therapy: 16%), dry skin (monotherapy: 4%; combination therapy: 10%), increased sweating (monotherapy: 6%; combination therapy: 6%), rash (monotherapy: 5%; combination therapy: 8%), and eczema (monotherapy: 1%; combination therapy: 5%) have been reported in CHC patients.</p>
<p></p>
<p>Lipodystrophy acquired was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.</p>
<p></p>
<p>Skin disorders associated with combination therapy have included lichenoid eruptions and maculopapular rashes.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Alopecia (up to 28%), pruritus (up to 25%), dermatitis (up to 16%), rash (up to 16%), dry skin (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Increased sweating, eczema, psoriasis, urticaria, skin disorder, photosensitivity reaction, night sweats, herpes simplex, lipodystrophy acquired</p>
<p><b>Uncommon</b> (0.1% to 1%): Skin infection</p>
<p><b>Very rare</b> (less than 0.01%): Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, erythema multiforme</p>
<p><b>Frequency not reported</b>: Lichenoid eruptions, maculopapular rashes, drug-induced Sweet's syndrome</p>
<p><b>Postmarketing reports</b>: Serious skin reactions<sup>[Ref]</sup></p><h3>Local</h3><p>Injection site reactions (monotherapy: 22%; combination therapy: 23%) have been reported in CHC patients.</p>
<p></p>
<p>Skin disorders associated with combination therapy have included cutaneous necrosis at peginterferon alfa-2a injection sites.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Injection site reactions (up to 28%)</p>
<p><b>Frequency not reported</b>: Cutaneous necrosis at injection sites, hyperpigmentation around/over injection sites<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated ALT (up to 27%)</p>
<p><b>Common</b> (1% to 10%): Hepatic decompensation</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatic dysfunction</p>
<p><b>Rare</b> (0.01% to 0.1%): Hepatic failure, fatty liver, cholangitis</p>
<p><b>Frequency not reported</b>: Elevated ALT occasionally associated with hyperbilirubinemia, exacerbations of hepatitis, hepatitis B flares, increased bilirubin<sup>[Ref]</sup></p><p>Transient ALT elevations reported during hepatitis B therapy.  ALT elevation greater than 10-fold higher than the upper limit of normal was reported in 12% and 18% during treatment and 7% and 12% posttreatment in HBeAg-negative and HBeAg-positive patients, respectively.</p>
<p></p>
<p>Hepatic decompensation has been reported in 2% of CHC patients coinfected with HIV.</p>
<p></p>
<p>The most common or important serious side effects reported during hepatitis B studies have included hepatitis B flares.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Anorexia (monotherapy: up to 17%; combination therapy: 24%) and weight decrease (monotherapy: 4%; combination therapy: 10%) have been reported in CHC patients.</p>
<p></p>
<p>Hyperlactacidemia/lactic acidosis was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Anorexia (up to 27%), weight decrease (up to 16%), decreased appetite (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Hyperlactacidemia/lactic acidosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Dehydration, diabetes mellitus</p>
<p><b>Rare</b> (0.01% to 0.1%): Diabetic ketoacidosis</p>
<p><b>Frequency not reported</b>: Elevated triglycerides, electrolyte disturbance (hypokalemia, hypocalcemia, hypophosphatemia), hyperglycemia, hypoglycemia<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Dyspnea (monotherapy: 4%; combination therapy: 13%), cough (monotherapy: 4%; combination therapy: 10%), and exertional dyspnea (monotherapy: less than 1%; combination therapy: 4%) have been reported in CHC patients.</p>
<p></p>
<p>Pneumonia, influenza, and pharyngolaryngeal pain were reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Cough (up to 19%), dyspnea (up to 15%)</p>
<p><b>Common</b> (1% to 10%): Pharyngitis, exertional dyspnea, epistaxis, nasopharyngitis, sinus congestion, nasal congestion, rhinitis, sore throat, bronchitis, upper respiratory tract infection, pulmonary congestion, chest tightness, pneumonia, influenza, pharyngolaryngeal pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Wheezing</p>
<p><b>Rare</b> (0.01% to 0.1%): Interstitial pneumonitis (including fatalities), pulmonary embolism</p>
<p><b>Frequency not reported</b>: Lower respiratory tract infection<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Development of neutralizing anti-interferon antibodies</p>
<p><b>Uncommon</b> (0.1% to 1%): Sarcoidosis</p>
<p><b>Rare</b> (0.01% to 0.1%): Systemic lupus erythematosus, rheumatoid arthritis</p>
<p><b>Frequency not reported</b>: Autoimmune phenomena, development of binding antibodies to peginterferon alfa-2a, Vogt-Koyanagi-Harada disease</p>
<p><b>Postmarketing reports</b>: Liver graft rejection, renal graft rejection</p>
<p></p>
<p>Alpha interferons:</p>
<p>-Frequency not reported: Development or exacerbation of autoimmune disorders (including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, systemic lupus erythematosus)<sup>[Ref]</sup></p><p>Examples of autoimmune phenomena include hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis, immune thrombocytopenic purpura, thyroiditis, psoriasis.</p>
<p></p>
<p>Sarcoidosis was reported in a 65-year-old man at the 7th month of therapy.  Most of the symptoms improved over the next 3 months after discontinuation of therapy.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia, palpitations</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypertension</p>
<p><b>Rare</b> (0.01% to 0.1%): Myocardial infarction, congestive heart failure, cardiomyopathy, angina, arrhythmia, atrial fibrillation, pericarditis, supraventricular tachycardia, endocarditis, vasculitis</p>
<p><b>Frequency not reported</b>: Peripheral ischemia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Blurred vision (monotherapy: 4%; combination therapy: 5%) has been reported in CHC patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Blurred vision, eye pain, eye inflammation, xerophthalmia</p>
<p><b>Uncommon</b> (0.1% to 1%): Retinal hemorrhage</p>
<p><b>Rare</b> (0.01% to 0.1%): Optic neuropathy, papilledema, retinal vascular disorder, retinopathy, corneal ulcers</p>
<p><b>Very rare</b> (less than 0.01%): Vision loss</p>
<p><b>Postmarketing reports</b>: Serous retinal detachment<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Hypothyroidism (monotherapy: 3%; combination therapy: 4%) has been reported in CHC patients.</p><p><b>Common</b> (1% to 10%): Hypothyroidism, hyperthyroidism, clinically significant abnormal thyroid laboratory values</p>
<p><b>Uncommon</b> (0.1% to 1%): Thyroiditis</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Impotence, chromaturia<sup>[Ref]</sup></p><p>Chromaturia was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatic neoplasm</p>
<p><b>Frequency not reported</b>: Malignant hepatic neoplasm</p><h3>Hypersensitivity</h3><p>Anaphylactic shock has been reported during hepatitis B studies.</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis</p>
<p><b>Frequency not reported</b>: Anaphylactic shock</p><h3>Renal</h3><p><b>Rare</b> (0.01% to 0.1%): Renal insufficiency</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Guilabert A,  Bosch X,  Julia M,  Iranzo P,  Mascaro JM Jr "Pegylated interferon alfa-induced sarcoidosis: two sides of the same coin." Br J Dermatol 152 (2005): 377-9</p><p id="ref_4">4. "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories, Nutley, NJ. </p><p id="ref_5">5. Dove LM,  Rosen RC,  Ramcharran D, et al. "Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C." Gastroenterology 137 (2009): 873-84</p><p id="ref_6">6. Brito MO,  Doyle T "Movement and extrapyramidal disorders associated with interferon use in HIV/hepatitis C coinfection." AIDS 21 (2007): 1987-9</p><p id="ref_7">7. Mlika RB,  Kerkeni N,  Marrak H,  Fenniche S,  Mokhtar I,  Debbiche A "Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature." Int J Dermatol 52 (2013): 643-4</p><p id="ref_8">8. Peck-Radosavljevic M,  Wichlas M,  Homoncik-Kraml M, et al. "Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha." Gastroenterology 123 (2002): 141-51</p><p id="ref_9">9. Espinosa M,  Arenas MD,  Aumente MD, et al. "Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients." Clin Nephrol 67 (2007): 366-73</p><p id="ref_10">10. Arcasoy MO,  Rockey DC,  Heneghan MA "Pure red cell aplasia following pegylated interferon alpha treatment." Am J Med 117 (2004): 619-20</p><p id="ref_11">11. Mize DS,  Riley TR "Retrospective analysis of the effect of pegylated interferon alpha on platelet count in patients with chronic Hepatitis C." Am J Gastroenterol 98(9S) (2003): S96</p><p id="ref_12">12. Udina M,  Castellvi P,  Moreno-Espana J, et al. "Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis." J Clin Psychiatry 73 (2012): 1128-38</p><p id="ref_13">13. Gheorghe L,  Cotruta B,  Trifu V,  Cotruta C,  Becheanu G,  Gheorghe C "Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy." Int J Dermatol 47 (2008): 957-9</p><p id="ref_14">14. Lin J,  Lott JP,  Amorosa VK,  Kovarik CL "Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin." J Am Acad Dermatol 60 (2009): 882-3</p></div>
<div class="more-resources" id="moreResources">
<h2>More about peginterferon alfa-2a</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>16 Reviews</li>
<li>Drug class: antiviral interferons</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Peginterferon alfa-2a Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Pegasys</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hepatitis B</li>
<li>Hepatitis C</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to peginterferon alfa-2a: subcutaneous kit, subcutaneous solution</i></p><h3>General</h3><p>During hepatitis C studies, at least 1 serious side effect was reported in 10% of chronic hepatitis C (CHC) patients and 19% of CHC patients coinfected with HIV.  The most common serious side effect was bacterial infection (including sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia).  Other serious side effects were suicide, suicidal ideation, psychosis, aggression, anxiety, drug abuse and drug overdose, angina, hepatic dysfunction, fatty liver, cholangitis, arrhythmia, diabetes mellitus, autoimmune phenomena (e.g., hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis), peripheral neuropathy, aplastic anemia, peptic ulcer, gastrointestinal bleeding, pancreatitis, colitis, corneal ulcer, pulmonary embolism, coma, myositis, cerebral hemorrhage, thrombotic thrombocytopenic purpura, psychotic disorder, and hallucination.  The most common side effects were psychiatric reactions (including depression, insomnia, irritability, anxiety), influenza-like symptoms (such as fatigue, pyrexia, myalgia, headache, rigors), anorexia, nausea and vomiting, diarrhea, arthralgias, injection site reactions, alopecia, and pruritus.  Psychiatric disorders, influenza-like syndrome (e.g., lethargy, fatigue, headache), dermatologic disorders, gastrointestinal disorders, and laboratory abnormalities (thrombocytopenia, neutropenia, anemia) were the most common reasons for discontinuation of therapy.</p><p></p><p>In clinical trials, patients with chronic hepatitis B had similar side effects as CHC patients using peginterferon alfa-2a monotherapy, except for exacerbations of hepatitis.  The most common or important serious side effects in the hepatitis B studies were infections (sepsis, appendicitis, tuberculosis, influenza), hepatitis B flares, thrombotic thrombocytopenic purpura, pyrexia, headache, fatigue, myalgia, alopecia, and anorexia.  Therapy was discontinued most often due to laboratory abnormalities (neutropenia, thrombocytopenia, ALT elevation).<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Headache (monotherapy: up to 54%; combination therapy: 43%), dizziness excluding vertigo (monotherapy: 16%; combination therapy: 14%), and memory impairment (monotherapy: 5%; combination therapy: 5%) have been reported in CHC patients.</p><p></p><p>Tinnitus was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.</p><p></p><p>A 40-year-old male coinfected with hepatitis C virus and HIV experienced chorea and akathisia coincident with peginterferon alfa-2a therapy.  He was administered subcutaneous peginterferon alfa-2a 180 mcg weekly and oral ribavirin 1 g daily.  At week 20 of therapy, the patient presented to the clinic complaining of irritability, difficulty in sleeping, and prominent choreiform involuntary movements with myoclonic activity of the upper and lower extremities.  He was diagnosed with chorea and akathisia.  He was treated with ropinirole, propranolol, and clonazepam.  Peginterferon alfa-2a and ribavirin were discontinued with complete resolution of symptoms after 5 days.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Dizziness (up to 89%), headache (up to 56%), concentration impairment</p><p><b>Common</b> (1% to 10%): Vertigo, syncope, migraine, memory impairment, weakness, hypoesthesia, hyperesthesia, paresthesia, tremor, taste disturbance, somnolence, tinnitus</p><p><b>Uncommon</b> (0.1% to 1%): Peripheral neuropathy, hearing loss</p><p><b>Rare</b> (0.01% to 0.1%): Cerebral hemorrhage, coma, convulsions, facial palsy</p><p><b>Frequency not reported</b>: Cerebral ischemia, chorea and akathisia</p><p><b>Postmarketing reports</b>: Seizures, hearing impairment<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Influenza-like signs/symptoms, fatigue/asthenia (up to 65%), pyrexia (up to 54%), fatigue (up to 51%), rigors (up to 35%), asthenia (up to 30%), pain (up to 11%), overall resistance mechanism disorders (up to 12%)</p><p><b>Common</b> (1% to 10%): Fever, chills, chest pain, influenza-like illness, malaise, lethargy, shivering, hot flushes, thirst, infections (fungal, viral, bacterial), peripheral edema, flushing, earache</p><p><b>Rare</b> (0.01% to 0.1%): Mucosal hyperpigmentation, otitis externa, substance overdose</p><p><b>Frequency not reported</b>: Bacterial infections (e.g., sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia), infections (appendicitis, tuberculosis, influenza)<sup>[Ref]</sup></p><p>Influenza-like signs and symptoms (fatigue/asthenia [monotherapy: 56%; combination therapy: 65%], pyrexia [monotherapy: up to 54%; combination therapy: 41%], rigors [monotherapy: 35%; combination therapy: 25%], pain [monotherapy: 11%; combination therapy: 10%]) and overall resistance mechanism disorders (monotherapy: 10%; combination therapy: 12%) have been reported in CHC patients.</p><p></p><p>The most common or important serious side effects reported during hepatitis B studies have included infections (sepsis, appendicitis, tuberculosis, influenza).</p><p></p><p>Fatigue has been reported in 24% of patients during hepatitis B studies.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Myalgia (monotherapy: up to 37%; combination therapy: 40%), arthralgia (monotherapy: 28%; combination therapy: 22%), and back pain (monotherapy: 9%; combination therapy: 5%) have been reported in CHC patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Myalgia (up to 44%), arthralgia (up to 32%)</p><p><b>Common</b> (1% to 10%): Back pain, arthritis, muscle weakness, bone pain, neck pain, musculoskeletal pain, muscle cramps</p><p><b>Rare</b> (0.01% to 0.1%): Myositis</p><p><b>Frequency not reported</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Neutropenia (monotherapy: 21%; combination therapy: up to 40%), lymphopenia (monotherapy: 3%; combination therapy: 14%), anemia (monotherapy: 2%; combination therapy: up to 14%), and thrombocytopenia (monotherapy: 5%; combination therapy: up to 8%) have been reported in CHC patients.</p><p></p><p>Moderate (absolute neutrophil count [ANC] 0.5 to 0.749 x 10[9]/L: 24%) and severe (ANC less than 0.5 x 10[9]/L: 5%) neutropenia was reported in patients using peginterferon alfa-2a plus ribavirin for 48 weeks.</p><p></p><p>In 1 study, CHC patients with advanced fibrosis or cirrhosis and baseline platelet counts as low as 50,000/mm3 were treated for 48 weeks.  Hematologic laboratory abnormalities in the first 20 weeks included ANC less than 750/mm3 (30%), hemoglobin less than 10 g/dL (26.3%), and platelets less than 50,000/mm3 (13%).</p><p></p><p>Neutropenia (40%), anemia (14%), and thrombocytopenia (8%) have been reported during treatment with peginterferon alfa-2a plus ribavirin in CHC patients coinfected with HIV.  Decrease in ANC levels below 500 cells/mm3 (monotherapy: 13%; combination therapy: 11%), decrease in platelets below 50,000/mm3 (monotherapy: 10%; combination therapy: 8%), and hemoglobin less than 10 g/dL (monotherapy: 7%; combination therapy: up to 28%) were reported in coinfected patients.</p><p></p><p>Laboratory abnormalities (thrombocytopenia, neutropenia, anemia) were among the most common reasons given for discontinuation of therapy.</p><p></p><p>The most common or important serious side effects reported during hepatitis B studies have included thrombotic thrombocytopenic purpura.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Neutropenia (up to 40%), anemia (up to 28%), lymphopenia (up to 14%)</p><p><b>Common</b> (1% to 10%): Thrombocytopenia, lymphadenopathy</p><p><b>Rare</b> (0.01% to 0.1%): Pancytopenia</p><p><b>Very rare</b> (less than 0.01%): Aplastic anemia, idiopathic or thrombotic thrombocytopenic purpura</p><p><b>Frequency not reported</b>: Leukopenia, decreased hemoglobin, decreased absolute CD4+ cell count (without decrease in CD4+ cell percentage)</p><p><b>Postmarketing reports</b>: Pure red cell aplasia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 40%), diarrhea (up to 26%), nausea/vomiting (up to 25%), abdominal pain (up to 15%), vomiting (up to 13%), upper abdominal pain (up to 12%)</p><p><b>Common</b> (1% to 10%): Dry mouth, dyspepsia, dysphagia, mouth ulceration, gingival bleeding, glossitis, stomatitis, flatulence, gastritis, gingivitis, cheilitis, constipation, oral candidiasis</p><p><b>Uncommon</b> (0.1% to 1%): Gastrointestinal bleeding</p><p><b>Rare</b> (0.01% to 0.1%): Tongue hyperpigmentation, peptic ulcer, pancreatitis</p><p><b>Frequency not reported</b>: Colitis, ischemic colitis, reversible pancreatic reaction (i.e., increased amylase/lipase with or without abdominal pain)</p><p><b>Postmarketing reports</b>: Tongue pigmentation<sup>[Ref]</sup></p><p>Gastrointestinal side effects were among the most common reasons given for discontinuation of therapy.</p><p></p><p>Nausea/vomiting (monotherapy: 24%; combination therapy: 25%), diarrhea (monotherapy: 16%; combination therapy: 11%), abdominal pain (monotherapy: 15%; combination therapy: 8%), dry mouth (monotherapy: 6%; combination therapy: 4%), and dyspepsia (monotherapy: less than 1%; combination therapy: 6%) have been reported in CHC patients.</p><p></p><p>Cheilitis was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects were among the most common reasons given for discontinuation of therapy.</p><p></p><p>Irritability/anxiety/nervousness (monotherapy: 19%; combination therapy: 33%), insomnia (monotherapy: 19%; combination therapy: 30%), depression (monotherapy: 18%; combination therapy: 20%), concentration impairment (monotherapy: 8%; combination therapy: 10%), and mood alteration (monotherapy: 3%; combination therapy: 5%) have been reported in CHC patients.</p><p></p><p>Affect lability and apathy were reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.</p><p></p><p>Impairment of desire, sexual satisfaction affected (potentially), and sexual dysfunction have been reported with peginterferon alfa-2a plus ribavirin in male patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Insomnia (up to 36%), irritability/anxiety/nervousness (up to 33%), irritability (up to 28%), depression (up to 27%), anxiety</p><p><b>Common</b> (1% to 10%): Concentration impairment, mood alteration, nightmares, aggression, emotional disorders, nervousness, decreased libido, affect lability, apathy</p><p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation, hallucinations</p><p><b>Rare</b> (0.01% to 0.1%): Suicide, psychotic disorder</p><p><b>Frequency not reported</b>: Psychosis, relapse of drug abuse/overdose, impairment of desire, sexual satisfaction affected (potentially), sexual dysfunction, mania, bipolar disorders</p><p><b>Postmarketing reports</b>: Homicidal ideation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic side effects were among the most common reasons given for discontinuation of therapy.</p><p></p><p>Alopecia (monotherapy: up to 23%; combination therapy: 28%), pruritus (monotherapy: 12%; combination therapy: 19%), dermatitis (monotherapy: 8%; combination therapy: 16%), dry skin (monotherapy: 4%; combination therapy: 10%), increased sweating (monotherapy: 6%; combination therapy: 6%), rash (monotherapy: 5%; combination therapy: 8%), and eczema (monotherapy: 1%; combination therapy: 5%) have been reported in CHC patients.</p><p></p><p>Lipodystrophy acquired was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.</p><p></p><p>Skin disorders associated with combination therapy have included lichenoid eruptions and maculopapular rashes.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Alopecia (up to 28%), pruritus (up to 25%), dermatitis (up to 16%), rash (up to 16%), dry skin (up to 13%)</p><p><b>Common</b> (1% to 10%): Increased sweating, eczema, psoriasis, urticaria, skin disorder, photosensitivity reaction, night sweats, herpes simplex, lipodystrophy acquired</p><p><b>Uncommon</b> (0.1% to 1%): Skin infection</p><p><b>Very rare</b> (less than 0.01%): Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, erythema multiforme</p><p><b>Frequency not reported</b>: Lichenoid eruptions, maculopapular rashes, drug-induced Sweet's syndrome</p><p><b>Postmarketing reports</b>: Serious skin reactions<sup>[Ref]</sup></p><h3>Local</h3><p>Injection site reactions (monotherapy: 22%; combination therapy: 23%) have been reported in CHC patients.</p><p></p><p>Skin disorders associated with combination therapy have included cutaneous necrosis at peginterferon alfa-2a injection sites.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Injection site reactions (up to 28%)</p><p><b>Frequency not reported</b>: Cutaneous necrosis at injection sites, hyperpigmentation around/over injection sites<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated ALT (up to 27%)</p><p><b>Common</b> (1% to 10%): Hepatic decompensation</p><p><b>Uncommon</b> (0.1% to 1%): Hepatic dysfunction</p><p><b>Rare</b> (0.01% to 0.1%): Hepatic failure, fatty liver, cholangitis</p><p><b>Frequency not reported</b>: Elevated ALT occasionally associated with hyperbilirubinemia, exacerbations of hepatitis, hepatitis B flares, increased bilirubin<sup>[Ref]</sup></p><p>Transient ALT elevations reported during hepatitis B therapy.  ALT elevation greater than 10-fold higher than the upper limit of normal was reported in 12% and 18% during treatment and 7% and 12% posttreatment in HBeAg-negative and HBeAg-positive patients, respectively.</p><p></p><p>Hepatic decompensation has been reported in 2% of CHC patients coinfected with HIV.</p><p></p><p>The most common or important serious side effects reported during hepatitis B studies have included hepatitis B flares.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Anorexia (monotherapy: up to 17%; combination therapy: 24%) and weight decrease (monotherapy: 4%; combination therapy: 10%) have been reported in CHC patients.</p><p></p><p>Hyperlactacidemia/lactic acidosis was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Anorexia (up to 27%), weight decrease (up to 16%), decreased appetite (up to 16%)</p><p><b>Common</b> (1% to 10%): Hyperlactacidemia/lactic acidosis</p><p><b>Uncommon</b> (0.1% to 1%): Dehydration, diabetes mellitus</p><p><b>Rare</b> (0.01% to 0.1%): Diabetic ketoacidosis</p><p><b>Frequency not reported</b>: Elevated triglycerides, electrolyte disturbance (hypokalemia, hypocalcemia, hypophosphatemia), hyperglycemia, hypoglycemia<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Dyspnea (monotherapy: 4%; combination therapy: 13%), cough (monotherapy: 4%; combination therapy: 10%), and exertional dyspnea (monotherapy: less than 1%; combination therapy: 4%) have been reported in CHC patients.</p><p></p><p>Pneumonia, influenza, and pharyngolaryngeal pain were reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Cough (up to 19%), dyspnea (up to 15%)</p><p><b>Common</b> (1% to 10%): Pharyngitis, exertional dyspnea, epistaxis, nasopharyngitis, sinus congestion, nasal congestion, rhinitis, sore throat, bronchitis, upper respiratory tract infection, pulmonary congestion, chest tightness, pneumonia, influenza, pharyngolaryngeal pain</p><p><b>Uncommon</b> (0.1% to 1%): Wheezing</p><p><b>Rare</b> (0.01% to 0.1%): Interstitial pneumonitis (including fatalities), pulmonary embolism</p><p><b>Frequency not reported</b>: Lower respiratory tract infection<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Development of neutralizing anti-interferon antibodies</p><p><b>Uncommon</b> (0.1% to 1%): Sarcoidosis</p><p><b>Rare</b> (0.01% to 0.1%): Systemic lupus erythematosus, rheumatoid arthritis</p><p><b>Frequency not reported</b>: Autoimmune phenomena, development of binding antibodies to peginterferon alfa-2a, Vogt-Koyanagi-Harada disease</p><p><b>Postmarketing reports</b>: Liver graft rejection, renal graft rejection</p><p></p><p>Alpha interferons:</p><p>-Frequency not reported: Development or exacerbation of autoimmune disorders (including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, systemic lupus erythematosus)<sup>[Ref]</sup></p><p>Examples of autoimmune phenomena include hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis, immune thrombocytopenic purpura, thyroiditis, psoriasis.</p><p></p><p>Sarcoidosis was reported in a 65-year-old man at the 7th month of therapy.  Most of the symptoms improved over the next 3 months after discontinuation of therapy.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia, palpitations</p><p><b>Uncommon</b> (0.1% to 1%): Hypertension</p><p><b>Rare</b> (0.01% to 0.1%): Myocardial infarction, congestive heart failure, cardiomyopathy, angina, arrhythmia, atrial fibrillation, pericarditis, supraventricular tachycardia, endocarditis, vasculitis</p><p><b>Frequency not reported</b>: Peripheral ischemia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Blurred vision (monotherapy: 4%; combination therapy: 5%) has been reported in CHC patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Blurred vision, eye pain, eye inflammation, xerophthalmia</p><p><b>Uncommon</b> (0.1% to 1%): Retinal hemorrhage</p><p><b>Rare</b> (0.01% to 0.1%): Optic neuropathy, papilledema, retinal vascular disorder, retinopathy, corneal ulcers</p><p><b>Very rare</b> (less than 0.01%): Vision loss</p><p><b>Postmarketing reports</b>: Serous retinal detachment<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Hypothyroidism (monotherapy: 3%; combination therapy: 4%) has been reported in CHC patients.</p><p><b>Common</b> (1% to 10%): Hypothyroidism, hyperthyroidism, clinically significant abnormal thyroid laboratory values</p><p><b>Uncommon</b> (0.1% to 1%): Thyroiditis</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Impotence, chromaturia<sup>[Ref]</sup></p><p>Chromaturia was reported in up to 2% of CHC patients coinfected with HIV using peginterferon alfa-2a plus ribavirin.<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatic neoplasm</p><p><b>Frequency not reported</b>: Malignant hepatic neoplasm</p><h3>Hypersensitivity</h3><p>Anaphylactic shock has been reported during hepatitis B studies.</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis</p><p><b>Frequency not reported</b>: Anaphylactic shock</p><h3>Renal</h3><p><b>Rare</b> (0.01% to 0.1%): Renal insufficiency</p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Guilabert A,  Bosch X,  Julia M,  Iranzo P,  Mascaro JM Jr "Pegylated interferon alfa-induced sarcoidosis: two sides of the same coin." Br J Dermatol 152 (2005): 377-9</p><p id="ref_4">4. "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories, Nutley, NJ. </p><p id="ref_5">5. Dove LM,  Rosen RC,  Ramcharran D, et al. "Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C." Gastroenterology 137 (2009): 873-84</p><p id="ref_6">6. Brito MO,  Doyle T "Movement and extrapyramidal disorders associated with interferon use in HIV/hepatitis C coinfection." AIDS 21 (2007): 1987-9</p><p id="ref_7">7. Mlika RB,  Kerkeni N,  Marrak H,  Fenniche S,  Mokhtar I,  Debbiche A "Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature." Int J Dermatol 52 (2013): 643-4</p><p id="ref_8">8. Peck-Radosavljevic M,  Wichlas M,  Homoncik-Kraml M, et al. "Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha." Gastroenterology 123 (2002): 141-51</p><p id="ref_9">9. Espinosa M,  Arenas MD,  Aumente MD, et al. "Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients." Clin Nephrol 67 (2007): 366-73</p><p id="ref_10">10. Arcasoy MO,  Rockey DC,  Heneghan MA "Pure red cell aplasia following pegylated interferon alpha treatment." Am J Med 117 (2004): 619-20</p><p id="ref_11">11. Mize DS,  Riley TR "Retrospective analysis of the effect of pegylated interferon alpha on platelet count in patients with chronic Hepatitis C." Am J Gastroenterol 98(9S) (2003): S96</p><p id="ref_12">12. Udina M,  Castellvi P,  Moreno-Espana J, et al. "Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis." J Clin Psychiatry 73 (2012): 1128-38</p><p id="ref_13">13. Gheorghe L,  Cotruta B,  Trifu V,  Cotruta C,  Becheanu G,  Gheorghe C "Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy." Int J Dermatol 47 (2008): 957-9</p><p id="ref_14">14. Lin J,  Lott JP,  Amorosa VK,  Kovarik CL "Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin." J Am Acad Dermatol 60 (2009): 882-3</p><h2>More about peginterferon alfa-2a</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>16 Reviews</li>
<li>Drug class: antiviral interferons</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Peginterferon alfa-2a Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hepatitis B</li>
<li>Hepatitis C</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>